BioCentury
ARTICLE | Clinical News

DAC:GLP-1: Phase II start

June 7, 2004 7:00 AM UTC

ConjuChem Inc. (TSE:CJC), Montreal, Quebec Product: DAC:GLP-1 Business: Endocrine Molecular target: Glucagon like peptide-1 (GLP-1) receptor Description: Analog of GLP-1 created using DAC technology I...